Andreas Argyrides
Stock Analyst at Oppenheimer
(4.43)
# 255
Out of 4,842 analysts
105
Total ratings
50%
Success rate
22.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LQDA Liquidia | Downgrades: Underperform | $13 | $14.71 | -11.62% | 7 | May 19, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Outperform | $14 → $4 | $0.58 | +589.66% | 5 | May 16, 2025 | |
| KRRO Korro Bio | Maintains: Outperform | $155 → $90 | $12.07 | +645.65% | 1 | May 13, 2025 | |
| PRQR ProQR Therapeutics | Maintains: Outperform | $15 → $9 | $1.77 | +409.92% | 1 | May 13, 2025 | |
| IFRX InflaRx | Initiates: Outperform | $6 | $0.83 | +627.27% | 1 | May 8, 2025 | |
| KROS Keros Therapeutics | Downgrades: Neutral | $47 → $15 | $13.96 | +7.45% | 8 | Jan 17, 2025 | |
| ASND Ascendis Pharma | Reiterates: Outperform | $181 | $161.88 | +11.81% | 9 | Nov 15, 2024 | |
| BNTC Benitec Biopharma | Initiates: Outperform | $35 | $15.45 | +126.54% | 1 | Oct 16, 2024 | |
| LRMR Larimar Therapeutics | Initiates: Outperform | $26 | $2.16 | +1,106.50% | 1 | Oct 16, 2024 | |
| RGLS Regulus Therapeutics | Reiterates: Outperform | $7 | $7.96 | -12.01% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $104 | $38.93 | +167.15% | 14 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $0.81 | +520.66% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $1.19 | +659.49% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $15.29 | +24.26% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $9 | $2.71 | +232.10% | 4 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $19.45 | +49.10% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $8.69 | +141.66% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $38.43 | +482.88% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $25.53 | +123.27% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $0.67 | - | 6 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $0.75 | +833.33% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $4.14 | +141.84% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.46 | +2,070.61% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $58.35 | +19.97% | 6 | Aug 1, 2023 |
Liquidia
May 19, 2025
Downgrades: Underperform
Price Target: $13
Current: $14.71
Upside: -11.62%
Rani Therapeutics Holdings
May 16, 2025
Maintains: Outperform
Price Target: $14 → $4
Current: $0.58
Upside: +589.66%
Korro Bio
May 13, 2025
Maintains: Outperform
Price Target: $155 → $90
Current: $12.07
Upside: +645.65%
ProQR Therapeutics
May 13, 2025
Maintains: Outperform
Price Target: $15 → $9
Current: $1.77
Upside: +409.92%
InflaRx
May 8, 2025
Initiates: Outperform
Price Target: $6
Current: $0.83
Upside: +627.27%
Keros Therapeutics
Jan 17, 2025
Downgrades: Neutral
Price Target: $47 → $15
Current: $13.96
Upside: +7.45%
Ascendis Pharma
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $161.88
Upside: +11.81%
Benitec Biopharma
Oct 16, 2024
Initiates: Outperform
Price Target: $35
Current: $15.45
Upside: +126.54%
Larimar Therapeutics
Oct 16, 2024
Initiates: Outperform
Price Target: $26
Current: $2.16
Upside: +1,106.50%
Regulus Therapeutics
Aug 14, 2024
Reiterates: Outperform
Price Target: $7
Current: $7.96
Upside: -12.01%
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $38.93
Upside: +167.15%
Jun 25, 2024
Initiates: Outperform
Price Target: $5
Current: $0.81
Upside: +520.66%
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $1.19
Upside: +659.49%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $15.29
Upside: +24.26%
Mar 7, 2024
Maintains: Outperform
Price Target: $4 → $9
Current: $2.71
Upside: +232.10%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $19.45
Upside: +49.10%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $8.69
Upside: +141.66%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $38.43
Upside: +482.88%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $25.53
Upside: +123.27%
Nov 16, 2023
Upgrades: Outperform
Price Target: n/a
Current: $0.67
Upside: -
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $0.75
Upside: +833.33%
Oct 10, 2023
Initiates: Outperform
Price Target: $10
Current: $4.14
Upside: +141.84%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.46
Upside: +2,070.61%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $58.35
Upside: +19.97%